Treatment strategy of end-stage renal disease related hyperparathyroidism before, during, and after the era of calcimimetics

Since 2004, end-stage renal disease related hyperparathyroidism patients are treated mainly with cinacalcet, which ceased to be subsidized through the Australian Pharmaceutical Benefits Scheme in 2015. We aimed to investigate the impact of these changes on the treatment strategy in the Australian end-stage renal disease population.

Source: Surgery - November 6, 2018 Category: Surgery Authors: Willemijn Y. van der Plas, Anton F. Engelsman, Marille Umakanthan, Amanda Mather, Stan B. Sidhu, Leigh W. Delbridge, Carol Pollock, David Waugh, Mark S. Sywak, Schelto Kruijff Source Type: research